keyword
MENU ▼
Read by QxMD icon Read
search

Cutaneous T cell Lymphoma

keyword
https://www.readbyqxmd.com/read/28812387/reply-to-recent-advances-in-systemic-targeted-therapy-for-cutaneous-t-cell-lymphoma
#1
Teresa Amaral, Claus Garbe
No abstract text is available yet for this article.
August 16, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28805086/brentuximab-vedotin-therapy-for-cd30-positive-cutaneous-t-cell-lymphoma-a-targeted-approach-to-management
#2
Julia J Scarisbrick
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Response rates >75% with manageable adverse effects in refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma led to accelerated approval for both. Phase II studies in CD30-expressing CTCL followed and showed similar efficacy, which was ratified in a Phase III trial of BV versus physician's choice (methotrexate or bexarotene) showing significant improved responses without increase in severe adverse effects although peripheral neuropathy is frequent...
August 14, 2017: Future Oncology
https://www.readbyqxmd.com/read/28803489/recent-advances-in-systemic-targeted-therapy-for-cutaneous-t-cell-lymphoma
#3
Daniel J Lewis, Ellen J Kim, Madeleine Duvic
No abstract text is available yet for this article.
August 14, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28802499/cutaneous-t-cell-lymphoma
#4
REVIEW
Melissa Pulitzer
Cutaneous T-cell lymphomas comprise a heterogeneous group of diseases characterized by monoclonal proliferations of T lymphocytes primarily involving skin, modified skin appendages, and some mucosal sites. This article addresses the basic clinical, histologic, and immunohistochemical characteristics of this group of diseases, with additional attention to evolving literature on dermoscopy, reflectance confocal microscopy, flow cytometry, and molecular data that may increasingly be applied to diagnostic and therapeutic algorithms in these diseases...
September 2017: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/28800143/immunohistochemistry-reveals-an-increased-proportion-of-myc-positive-cells-in-subcutaneous-panniculitis-like-t-cell-lymphoma-compared-with-lupus-panniculitis
#5
Sebastian Fernandez-Pol, Danielle De Stefano, Jinah Kim
BACKGROUND: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a malignant primary cutaneous T-cell lymphoma that shares significant clinical, histopathologic, and immunophenotypic overlap with lupus erythematosus panniculitis (LEP). METHODS: We performed immunohistochemistry for the MYC oncoprotein on 23 cases of SPTCL (one CD8 negative) and 12 cases of LEP to evaluate if there are quantitative or qualitative differences in protein expression of this marker in these entities...
August 11, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28796362/primary-cutaneous-acral-cd8-positive-t-cell-lymphoma-with-extra-cutaneous-involvement-a-long-standing-case-with-an-unexpected-progression
#6
Alberti-Violetti S, Fanoni D, Provasi M, Corti L, Venegoni L, Berti E
Primary cutaneous acral CD8+ T-cell lymphoma (acral CD8+ TCL) is a new provisional entity characterized by acral skin lesions and an indolent course. We describe an extraordinary case characterized by relapsed nodules with CD8+ cytotoxic infiltrates on the left ear. After 35 years, the skin lesions spread to other acral sites, and a mass with the same histological features as the other skin lesions appeared on the nose. Multiple courses of chemotherapy led to stable disease. Histological examinations carried out at different times showed the gradual transformation of the neoplastic cells with an increased proliferation index...
August 10, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28795410/clinicopathological-analysis-of-46-cases-with-cd4-and-or-cd56-immature-hematolymphoid-malignancy-reappraisal-of-blastic-plasmacytoid-dendritic-cell-and-related-neoplasms
#7
Yuka Suzuki, Seiichi Kato, Kei Kohno, Akira Satou, Ahmed E Eladl, Naoko Asano, Michihiro Kono, Yuichi Kato, Masafumi Taniwaki, Masashi Akiyama, Shigeo Nakamura
AIMS: Here we aimed to investigate the clinicopathological features of CD4+ and/or CD56+ immature hematolymphoid malignancy (iHLM), including blastic plasmacytoid dendritic cell neoplasm (BPDCN). METHODS AND RESULTS: We analysed the clinicopathological features of 46 patients consecutively diagnosed with CD4+/CD56+ iHLM. These cases were categorized into three groups based on their immunohistochemical expression of three plasmacytoid dendritic cell (pDC) markers (CD123, CD303, and TCL1): cutaneous BPDCN (n = 35), non-cutaneous BPDCN (n = 6), and non-BPDCN-type CD56+ neoplasms (n = 5)...
August 10, 2017: Histopathology
https://www.readbyqxmd.com/read/28795194/-treatment-of-rare-cutaneous-t%C3%A2-cell-lymphoma-and-blastic-plasmacytoid-dendritic-cell-neoplasm
#8
REVIEW
U Wehkamp, M Weichenthal
Among the group of primary cutaneous lymphomas several subtypes have very low incidence rates. Based on the revision of the WHO classification for lymphoid neoplasms (2016), an overview of rare cutaneous T‑cell lymphoma (CTCL) subtypes is given and therapeutic approaches are detailed. The prognosis of the different subtypes is highly variable underlining the importance of adequate stage and subtype adapted treatment. In cases of indolent subtypes topical treatment, e. g. topical corticosteroids or UV phototherapy are often sufficient...
August 9, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28793956/hypersensitivity-reaction-to-%C3%AE-lactam-antibiotics-in-patients-with-adult-t-cell-leukemia-lymphoma-treated-with-mogamulizumab%C3%A2
#9
Takeo Yasu, Yoichi Imai, Nobuhiro Ohno, Kaoru Uchimaru, Yosuke Kurokawa, Arinobu Tojo
Mogamulizumab (MOG) is a humanized anti-CCR4 monoclonal antibody that is highly cytotoxic for adult T-cell leukemia/lymphoma (ATL) cells. Most non-hematological adverse events are cutaneous adverse reactions in ATL patients. We reviewed the medical records of 24 patients with CCR4-positive aggressive ATL who had received MOG treatment. The incidence of MOG-induced cutaneous adverse reactions (MCARs) was 25% (6 patients). Four patients with MCAR had an interesting clinical course, compared with MCARs reported in previous reports...
August 10, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28770285/-treatment-of-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#10
REVIEW
J P Nicolay, C Assaf
Adequate therapeutic management of cutaneous T-cell lymphoma (CTCL) requires the identification of the exact CTCL stage and entity within the current WHO classification. There is no curative therapy for CTCL yet, so that treatment currently aims at improving symptoms and quality of life as well as reducing relapse rates. The treatment has to be stage-adapted. Therapeutic options comprise skin-directed as well as systemic treatment. In early stages, phototherapy and local steroids are the first-line therapeutic options...
August 2, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28766736/cutaneous-intravascular-nk-t-cell-lymphoma-with-peculiar-immunophenotype
#11
Victoria Alegría-Landa, Félix Manzarbeitia, Maria Gabriela Salvatierra Calderón, Luis Requena, Socorro María Rodríguez-Pinilla
Intravascular lymphoma (IVL) is a rare entity. Most cases are a variant of extranodal diffuse large B-cell lymphoma, and fewer than 10% of the published cases are of T-cell origin. Only intravascular B-cell lymphoma is recognized as a distinct entity in the most recent WHO classification of lymphoproliferative disorders. We describe a case of cutaneous NK/T IVL, with a cytotoxic immunophenotype and EBV positivity. However, our case was immunohistochemically negative not only for TCR-βF1 and TCR-γ (TCR-silent), but also for CD56, making it the first triple-negative NK/T IVL case to be described...
August 2, 2017: Histopathology
https://www.readbyqxmd.com/read/28766547/-breast-implant-associated-anaplastic-large-cell-lymphoma-a-case-report-and-a-review-of-literature
#12
N G Chernova, E E Zvonkov, A M Kovrigina, A B Sudarikov, D S Badmazhapova, N G Gabeeva, T N Obukhova, S R Karagyulyan, V G Savchenko
Breast implant-associated anaplastic large-cell lymphoma will be identified as a separate nosological entity in the 2017 adapted WHO classification due to differences in its clinical presentations, pathogenesis, and prognosis with those of nodal and cutaneous anaplastic large-cell lymphomas. The paper gives a review of the literature and describes the authors' own clinical case of common breast implant-associated anaplastic large-cell lymphoma involving breast tissue, axillary lymph nodes, anterior chest muscles, and bone marrow...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28762479/brentuximab-vedotin-in-cd30-primary-cutaneous-t-cell-lymphomas-a-review-and-analysis-of-existing-data
#13
Tyler H Enos, Lawrence S Feigenbaum, Heather W Wickless
BACKGROUND: The utility of brentuximab vedotin (BV) in CD30(+) systemic lymphomas is established, however evidence for treating primary cutaneous lymphoma remains limited. This study aimed to evaluate BV in treating CD30(+) transformed mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL). METHODS: A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid-MEDLINE(®) and PubMed databases...
August 1, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28749588/primary-cutaneous-cd4-positive-small-medium-sized-pleomorphic-t-cell-lymphoproliferative-disorder-report-of-a-case-and-review-of-the-literature
#14
Brett H Keeling, Alde Carlo P Gavino, Joan Admirand, Anthony C Soldano
Primary cutaneous small/medium-sized T-cell lymphoma (PCSM-TCL), which was included in the WHO-EORTC classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as a lymphoproliferative disorder (PCSM-TCLPD) due to its indolent behavior and uncertain malignant potential. Treatment with local therapies is usually curative, though there have been reports of aggressive, systemic disease. This spectrum of disease behavior evokes the consideration that this entity may actually be multiple diseases with a shared clinicopathologic features rather than a singular disease process with a variety of behaviors...
July 27, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28748653/oral-bexarotene-for-post-transplant-cutaneous-t-cell-lymphoma
#15
Daniel J Lewis, Simo Huang, Madeleine Duvic
Organ transplant recipients receiving immunosuppression have an increased risk of developing post-transplant lymphoproliferative diseases (PTLDs). Traditionally, PTLDs refer to Epstein-Barr virus (EBV)-induced B-cell lymphoma. However, post-transplant T-cell lymphoma may also occur and tends to have a poorer response to reduced immunosuppressive therapy. As such, additional therapy is often needed for post-transplant T-cell lymphoma, including post-transplant cutaneous T-cell lymphoma (PT-CTCL). We present only the third case of PT-CTCL occurring after liver transplantation...
July 26, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28729399/decitabine-priming-enhances-mucin-1-inhibition-mediated-disruption-of-redox-homeostasis-in-cutaneous-t-cell-lymphoma
#16
Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A Clark, Thomas S Kupper, Dina Stroopinsky, Athalia Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Kufe, David Avigan
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous neoplasm and patients with relapsed/refractory disease exhibit resistance to standard therapies. We have previously demonstrated that the MUC1-C oncoprotein plays a critical role in protection from oxidative stress in CTCL cells. Targeting of MUC1-C with a pharmacologic inhibitor, GO-203, was associated with apoptosis in CTCL. However, disease responses were incomplete underscoring the need for combinatorial strategies that could exploit the vulnerability of CTCL cells to oxidative signals...
July 20, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28721937/-18-f-fluorodeoxyglucose-positron-emission-tomography-is-more-sensitive-than-computed-tomography-in-initial-staging-of-patients-with-an-anaplastic-t-cell-lymphoma-first-presenting-in-the-skin
#17
Caroline Ram-Wolff, Laetitia Vercellino, Pauline Brice, Roberta La Selva, Martine Bagot
BACKGROUND: The role of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in the evaluation of anaplastic large-cell lymphoma (ALCL) first presenting in the skin is not well established, while computed tomography (CT) is used as a standard procedure. OBJECTIVES: The aim of this study was to evaluate the use of FDG-PET versus CT at initial staging of ALCL first presenting in the skin. MATERIALS & METHODS: Eleven cases of ALCL first presenting in the skin who underwent both FDG-PET and CT were retrospectively analysed...
July 19, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/28719434/primary-cutaneous-small-medium-cd4-t-cell-lymphoproliferative-disorder-occurring-in-a-patient-with-metastatic-melanoma
#18
Jonathan J Davick, Elizabeth Gaughan, Megan Barry, Alejandro A Gru
Therapeutic agents designed to stimulate the immune system are now cornerstones in the treatment of metastatic melanoma. These drugs promote lymphocyte growth and survival, which could plausibly result in clinical lymphoproliferative disorders. We report the case of a 62-year-old female with metastatic melanoma who developed primary cutaneous small/medium CD4 T-cell lymphoproliferative disorder (PC-SMTCL) after treatment with vemurafenib and recombinant high-dose interleukin-2 (IL-2). The patient developed a painless red papule behind the ear...
July 14, 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28712310/primary-cutaneous-peripheral-t-cell-lymphoma-in-a-sporotrichoid-pattern-a-case-report
#19
Daniel J Lewis, Harina Vin, Tiffany Hinojosa, Michael T Tetzlaff, Bouthaina S Dabaja, Madeleine Duvic
We present the extraordinary case of a 72-year-old man with a history of primary cutaneous peripheral T-cell lymphoma not otherwise specified (pcPTCL-NOS) previously controlled with topical agents who developed tumours in a sporotrichoid pattern. Culture of the tumours was negative, and histopathology showed findings consistent with recurrent pcPTCL. The tumours were successfully treated with localised radiation therapy. Sporotrichoid lesions are an extremely rare and atypical presentation of cutaneous lymphoma, with only 2 other cases reported in the literature...
July 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28712170/characteristics-and-outcomes-of-anaplastic-large-cell-lymphoma-patients-a-single-centre-experience
#20
Sohail Athar, Neelam Siddiqui, Abdul Hameed
BACKGROUND: Anaplastic large cell lymphoma (ALCL) is the second most common T cell lymphoma and 2% of all non-hodgkin lymphoma (NHL). It is an aggressive lymphoma with three subtypes, primary cutaneous ALCL, primary systemic ALK +ve ALCL and primary systemic ALK-ve ALCL depending upon rearrangement of Anaplastic Lymphoma Kinase (ALK) gene into ALK +ve and ALK -ve ALCL. Purpose of study is to determine the outcome of patients with ALCL treated at our institute. METHODS: In this retrospective analysis, 49 patients with ALCL from 2000 to 2012 were included...
January 2017: Journal of Ayub Medical College, Abbottabad: JAMC
keyword
keyword
6668
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"